Literature DB >> 17151174

No improvement of posttraumatic stress disorder symptoms with guanfacine treatment.

Thomas C Neylan1, Maryann Lenoci, Kristin W Samuelson, Thomas J Metzler, Clare Henn-Haase, Robert W Hierholzer, Steven E Lindley, Christian Otte, Frank B Schoenfeld, Jerome A Yesavage, Charles R Marmar.   

Abstract

OBJECTIVE: The authors report an 8-week, double-blind, randomized controlled trial of guanfacine versus placebo for posttraumatic stress disorder (PTSD).
METHOD: Veterans with chronic PTSD who were medication-free or receiving stable pharmacotherapy were randomly assigned to guanfacine (N=29) versus placebo (N=34).
RESULTS: Guanfacine had no effect on PTSD symptoms, subjective sleep quality, or general mood disturbances. Guanfacine was associated with a number of side effects.
CONCLUSIONS: These results do not support the use of alpha 2 agonists in veterans with chronic PTSD.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17151174     DOI： 10.1176/appi.ajp.163.12.2186

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN： 0002-953X            Impact factor:   18.112


  26 in total

Review 1.  Pharmacologic alternatives to antidepressants in posttraumatic stress disorder: a systematic review.

Authors:  William Berger; Mauro V Mendlowicz; Carla Marques-Portella; Gustavo Kinrys; Leonardo F Fontenelle; Charles R Marmar; Ivan Figueira
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2008-12-24       Impact factor: 5.067

2.  Treatment of insomnia in post--traumatic stress disorder.

Authors:  Nick J Coupland
Journal:  J Psychiatry Neurosci       Date:  2009-09       Impact factor: 6.186

Review 3.  Translating Molecular and Neuroendocrine Findings in Posttraumatic Stress Disorder and Resilience to Novel Therapies.

Authors:  Jonathan DePierro; Lauren Lepow; Adriana Feder; Rachel Yehuda
Journal:  Biol Psychiatry       Date:  2019-07-24       Impact factor: 13.382

Review 4.  Pharmacological treatment of PTSD - established and new approaches.

Authors:  Thomas Steckler; Victoria Risbrough
Journal:  Neuropharmacology       Date:  2011-06-29       Impact factor: 5.250

5.  Posttraumatic Stress Disorder: an integrated overview and neurobiological rationale for pharmacology.

Authors:  Benjamin Kelmendi; Thomas G Adams; Steven Southwick; Chadi G Abdallah; John H Krystal
Journal:  Clin Psychol (New York)       Date:  2017-07-18

Review 6.  Post-traumatic stress disorder: emerging concepts of pharmacotherapy.

Authors:  Dewleen G Baker; Caroline M Nievergelt; Victoria B Risbrough
Journal:  Expert Opin Emerg Drugs       Date:  2009-06       Impact factor: 4.191

Review 7.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

Review 8.  Targeting memory processes with drugs to prevent or cure PTSD.

Authors:  Christopher K Cain; George D Maynard; John H Kehne
Journal:  Expert Opin Investig Drugs       Date:  2012-07-27       Impact factor: 6.206

Review 9.  Pharmacotherapy in post-traumatic stress disorder: evidence from randomized controlled trials.

Authors:  Gregory M Sullivan; Yuval Neria
Journal:  Curr Opin Investig Drugs       Date:  2009-01

Review 10.  Pharmacological treatment of comorbid PTSD and substance use disorder: recent progress.

Authors:  Mehmet Sofuoglu; Robert Rosenheck; Ismene Petrakis
Journal:  Addict Behav       Date:  2013-08-22       Impact factor: 3.913
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.